Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution...
Reexamination Certificate
2005-06-23
2008-08-12
Leith, Patricia (Department: 1655)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
Reexamination Certificate
active
07410659
ABSTRACT:
Compositions and methods for the treatment of peripheral neural and vascular ailments are disclosed. The method comprises administering a flavonoid compound with antioxidant properties, optionally formulated in a acceptable carrier. This compound or combination of compounds provides significant, effective relief of the symptoms of peripheral neural or vascular ailments. In addition, the compositions, when used according to the methods of the present invention, do not exhibit the severe side effects of many prior art compositions proposed for treatment of these ailments.
REFERENCES:
patent: 4147795 (1979-04-01), Sarges
patent: 4210667 (1980-07-01), Sarges et al.
patent: 4232040 (1980-11-01), Waterbury
patent: 4250097 (1981-02-01), Pfister
patent: 4591600 (1986-05-01), Creuzet et al.
patent: 4617187 (1986-10-01), Okuyama et al.
patent: 4627973 (1986-12-01), Moran et al.
patent: 4822816 (1989-04-01), Markham
patent: 4997649 (1991-03-01), Papaconstantin et al.
patent: 5011840 (1991-04-01), Sarges
patent: 5043323 (1991-08-01), Bombardelli et al.
patent: 5070085 (1991-12-01), Markham
patent: 5122536 (1992-06-01), Perricone
patent: 5194248 (1993-03-01), Holick
patent: 5545398 (1996-08-01), Perricone
patent: 5550249 (1996-08-01), Della Valle et al.
patent: 5561110 (1996-10-01), Michaelis et al.
patent: 5571441 (1996-11-01), Andon et al.
patent: 5574063 (1996-11-01), Perricone
patent: 5595982 (1997-01-01), Harless
patent: 5607666 (1997-03-01), Masson et al.
patent: 5614224 (1997-03-01), Womack
patent: 5626868 (1997-05-01), Morancais et al.
patent: 5648083 (1997-07-01), Blieszner et al.
patent: 5660818 (1997-08-01), Dubief et al.
patent: 5665360 (1997-09-01), Mann
patent: 5665367 (1997-09-01), Burger et al.
patent: 5686082 (1997-11-01), N'Guyen
patent: 5686367 (1997-11-01), Hayashi
patent: 5709868 (1998-01-01), Perricone
patent: 5710177 (1998-01-01), Sauermann et al.
patent: 5725844 (1998-03-01), Gers-Barlag et al.
patent: 5770260 (1998-06-01), Fukuyama et al.
patent: 5776460 (1998-07-01), Kim et al.
patent: 5804168 (1998-09-01), Murad
patent: 5824666 (1998-10-01), Deckner et al.
patent: 5840736 (1998-11-01), Zelle et al.
patent: 5866578 (1999-02-01), Mylari et al.
patent: 5872140 (1999-02-01), Hesse et al.
patent: 5876737 (1999-03-01), Schonrock et al.
patent: 5883086 (1999-03-01), Craft
patent: 5922335 (1999-07-01), Ptchelintasev
patent: 5945090 (1999-08-01), Randall et al.
patent: 5948443 (1999-09-01), Riley et al.
patent: 5952391 (1999-09-01), Gers-Barlag et al.
patent: 5958379 (1999-09-01), Regenold et al.
patent: 5972359 (1999-10-01), Sine et al.
patent: 5972923 (1999-10-01), Simpkins et al.
patent: 5972999 (1999-10-01), Murad
patent: 5976568 (1999-11-01), Riley
patent: 5976579 (1999-11-01), McLean
patent: 5977184 (1999-11-01), Birdsall et al.
patent: 5981594 (1999-11-01), Okamoto et al.
patent: 5998394 (1999-12-01), Voorhees et al.
patent: 6048886 (2000-04-01), Neigut
patent: 6051602 (2000-04-01), Bissett
patent: 6054128 (2000-04-01), Wakat
patent: 6069168 (2000-05-01), Horrobin et al.
patent: 6103709 (2000-08-01), Norman et al.
patent: 6103756 (2000-08-01), Gorsek
patent: 6121243 (2000-09-01), Lanzendorfer et al.
patent: 6162801 (2000-12-01), Kita
patent: 6296861 (2001-10-01), Perricone
patent: 6299896 (2001-10-01), Cooper et al.
patent: 6423747 (2002-07-01), Lanzendorfer et al.
patent: 6444221 (2002-09-01), Shapiro
patent: 6451837 (2002-09-01), Baskys
patent: 6455057 (2002-09-01), Barrett et al.
patent: 6555573 (2003-04-01), Rosenbloom
patent: 6562794 (2003-05-01), Lanzendorfer et al.
patent: 6576660 (2003-06-01), Liao et al.
patent: 6592896 (2003-07-01), Rosenbloom
patent: 6596313 (2003-07-01), Rosenbloom
patent: 6596761 (2003-07-01), Lanzendorfer et al.
patent: 7083813 (2006-08-01), Rosenbloom
patent: 2280093 (1998-06-01), None
patent: 1283037 (2003-02-01), None
patent: 60-120812 (1985-06-01), None
patent: 01096106 (1989-04-01), None
patent: 3232851 (1991-10-01), None
patent: 07324037 (1995-12-01), None
patent: 200080044 (2000-03-01), None
patent: WO9626207 (1996-08-01), None
patent: WO 97/18817 (1997-05-01), None
patent: 9831381 (1998-07-01), None
patent: 9841113 (1998-09-01), None
patent: 0011968 (2000-03-01), None
patent: 0035848 (2000-06-01), None
patent: 0059522 (2000-10-01), None
Choi et al. (-)Epigallocatechin Galate and Quercetin Enhance Survival Signaling in Response to Oxidant-Induced Human Endothelial Apoptosis; The Journal of Nutrition; Apr. 2005; 135, 4; pp. 707-713.
Lenhard et al. Sharing the Pain; Diabetes Care, May 2003; 26, 5; pp. 1606-1607.
Baird, Stuart A. et al., “Anhydrosis in the Diabetic Foot: A Comparison of Two Urea Creams—Research,” The Diabetic Foot, 2003.
Fukuoka, Masami et al., “Tacalcitol, An Active Vitamin D3, Induces Nerve Growth Factor Production in Human Epidermal Keratinocytes,” Skin Pharmacology and Applied Skin Physiology, 2001, 226-233, vol. 14.
Elliott Middleton, Jr., Chithan Kandaswami and Theoharis C. Theoharides,The effects of Plant Flavnoids on Mammalian Cells: Implications for Inflammation, Heart Disease and Cancer, vol. 52, Issue 4, 673-751, Dec. 2000.
Rona, Z.: Treating Peripheral Neuropathy; Toronto Star, Aug. 2, 1998, pp. 1-2.
Nuraliev et al., The Efficacy of Quercetin In Alloxan Diabetes, Eksperimental 'naia Iklinicheskia farmakologiia (Jan.-Feb. 1992) 55 (1) 42-4.
Database on stn. Institute products research, (St. Croix, Minn, USA) No. 21449990, McKenna, et al., Efficiency, safety and use of gingko biloba, Sep.-Oct. 2001.
Database Medline on STn, Royal Free and Unversity college Medical School Smith, P.D. et al., Micronized purified favonoid fraction and the treatment of chronic venous insufficiency: Microcirculation, pp. S3-S40, 2000.
Ohguro N, et al., “Topical Aldose reductase inhibitor for correcting corneal cndothelial changes in diabetic patients”,Medscape Medline Abstract, Dec. 1995.
Coles, L.S., M.D., “Quercetin:A Review of Clinical Applications”,Natural Medicine Online, pp. 1-5.
Singh J.P., et al., “Role of Nitric Oxide in Pain”,Academic Press, 2000.
Kuroda, R., et al., “The Neuronal NO Synthase Inhibitor 7-nitro-indazole facilitates the antinociception elicited by the electrical stimulation of the secondary somatosensory cortex in the rat”,Academic Press, 2000.
Mitchell, T., “Over-the Counter Drup is Treatment for Alzheimer's”,LE Magazine, Nov. 2000, pp. 1-9.
Ross D, et al., “Ascorbate 6-palmitate protectes human erythrocytes from oxidative damage”,Free Radic Biol MedJan. 1999;26(1-2):81-9.
Medscape Medline Abstract, “Aldose reductase: a window to the treatment of diabetic complications?” by Crabbe MJ and Goode D, Jul. 1998.
Thirugnanasambantham P, et al., “Analgesic activity of certain flavone derivatives: a structure-activity study”,Clin Exp Pharmacol PhysiolJan. 1993;20(1):59-63.
Guillausseau PJ, Preventive treatment of diabetic micorangiopathy: blocking the pathogenic mechanisms,Diabete Metab, 1994;20(2 Pt 2):219-28.
McAuliffe AV et al., “Administration of ascorbic acid and an aldose reductase inhibitor (tolrestat) in diabetes: effect on urinary albumin excreation”NephronNov. 1998;80(3):277-84.
Hosotani H, et al., “Effects of topical aldose reductase inhibitor CT-112 on corneal sensitivity of diabetic rats”Curr Eye ResOct. 1996;15(10):1005-7.
Haraguchi, Ho., et al., “Inhibition of aldose reductase by dihydroflavonols inEngelhardtia chrysolepisand effects on other enzymes”, Medscape Medline Abstract, Jun. 1996.
McCarty ME, Medscape Medline Abstract, “Nitric oxide deficiency, leukocyte activation and resultant ishcemia are crucial to the pathogenesis of diabetic retinopathy
europathy—preventive potential of antioxidants, essential fatty acids, chromium, ginkgolides, and pentoxifylline” May 1998.
Boulton, AJ., et al., Medscape Medline Abstract, “Diabetic neuropathy” Jul. 1998.
Tutuncu NB., et al., Medscape Medline Abstract, “Reversal of defective nerve conduction with vitamin E supplement
Knoble & Yoshida & Dunleavy LLC
Leith Patricia
The Quigley Corporation
LandOfFree
Methods for the treatment of peripheral neural and vascular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the treatment of peripheral neural and vascular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of peripheral neural and vascular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4004315